Effect of manassantin B, a lignan isolated from Saururus chinensis, on lipopolysaccharide-induced interleukin-1beta in RAW 264.7 cells.
10.4097/kjae.2012.62.2.161
- Author:
Hwan Chul PARK
1
;
Hong Beom BAE
;
Cheol Won JEONG
;
Seong Heon LEE
;
Hye Jin JEUNG
;
Sang Hyun KWAK
Author Information
1. Department of Anesthesiology and Pain Medicine, Chonnam Nationanl University Hospital, Gwangju, Korea. shkwak@jnu.ac.kr
- Publication Type:Original Article
- Keywords:
Interleukin-1beta;
Lipopolysaccharides;
Manassantin B;
Mitogen-activated protein kinase
- MeSH:
Acute Lung Injury;
Capillaries;
Cytokines;
Extracellular Signal-Regulated MAP Kinases;
Furans;
Hypotension;
Interleukin-1beta;
Interleukins;
Lipopolysaccharides;
Macrophages;
p38 Mitogen-Activated Protein Kinases;
Pathologic Processes;
Phosphorylation;
Phosphotransferases;
Protein Kinases;
Saururaceae;
Sepsis;
Shock, Septic
- From:Korean Journal of Anesthesiology
2012;62(2):161-165
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Elevated systemic levels of pro-inflammatory cytokines cause hypotension during septic shock and induce capillary leakage in acute lung injury. Manassantin B has anti-inflammatory and anti-plasmoidal properties. This study examined the effects of manassantin B on lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages. METHODS: RAW 264.7 macrophage cells were incubated without or with (1, 3 and 10 microM) manassantin B and without or with (100 ng/ml) LPS. Manassantin B dissolved in phosphate buffered saline was added to the medium 1 h prior to the addition of LPS. The degree of activation of mitogen-activated protein kinase (MAPK) including extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun amino terminal kinases (JNK) and p38 MAPK, and the level of interleukin (IL)-1beta were determined 30 min and 24 h after the addition of LPS respectively. RESULTS: Manassantin B inhibited the production of IL-1beta and attenuated the phosphorylations of ERK1/2 and p38 MAPK, but not that of JNK, in RAW 264.7 cells treated with LPS. CONCLUSIONS: Manassantin B reduces LPS-induced IL-1beta expression through effects on ERK1/2- and p38 MAPK-mediated pathways. Manassantin B has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury.
